207_Combined course Presentations

3) Ongoing study on the role of altered fractionation: the CONVERT trial



Phase III randomized trial



447 patients enrolled, accrual closed, results expected very soon.



The results will be crucial in determining the best standard regimen for LD-SCLC Higher dose of radiation in the “once-daily” arm, compared to the hyperfractionated one (66 Gy vs 45)





Primary endpoint: OS

Faivre-Finn C. et al. BMJ 2016;6